Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
CTS | Change of Name and Principal Place of Business | 10/12/08 | ||
CTS | Appendix 3B - Options | 01/12/08 | ||
CTS | Change of Director's Interest Notice | 01/12/08 | ||
CTS | Results of Meeting | 26/11/08 | ||
CTSChange of Name and Principal Place of Business | |||
10/12/08 | 234.59KB | ||
CTSAppendix 3B - Options | |||
01/12/08 | 88.12KB | ||
CTSChange of Director's Interest Notice | |||
01/12/08 | 30.06KB | ||
CTSResults of Meeting | |||
26/11/08 | 73.37KB | ||